Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience
- 110 Downloads
To investigate the prevalence of and factors’ association with receiving suboptimal neoadjuvant chemotherapy (NAC) and its impact on survival outcomes in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy (RC).
We reviewed 1119 patients treated with NAC and/or RC for cT2-cT4N0M0 BC. Patients were segregated into three groups: (i) suboptimal NAC (received < 3 cycles of cisplatin-based NAC or non-cisplatin-based regimen), (ii) optimal NAC and (iii) no NAC. Clinical characteristics were compared among groups. Logistic regression analyses tested the association between clinical variables and the odds of receiving suboptimal NAC. To adjust for potential baseline confounders, propensity score matching was performed. Pathologic outcomes were compared between groups and Cox regression analyses tested the risk factors associated with recurrence, overall (OM) and cancer-specific mortality (CSM).
Before matching, 84/315 (26.6%) patients received a suboptimal NAC regimen. Lower general health status and impaired renal functions were the most significant factors associated with the administration of a suboptimal NAC. After matching, the optimal NAC group achieved higher rates of complete pathological response as compared to the suboptimal group (p = 0.03). Suboptimal NAC (HR 1.77; p = 0.015) and no NAC (HR 1.52; p = 0.03) were both associated with higher risk of recurrence and OM (HR 1.71; p = 0.02 and HR 1.61; p = 0.02) as compared to optimal NAC.
One out of four MIBC patients received a suboptimal NAC regimen before RC. Receiving a suboptimal NAC regimen was associated with worse disease recurrence and survival outcomes following surgery, as compared to an optimal NAC regimen.
KeywordsBladder cancer Neoadjuvant chemotherapy Cisplatin Risk factors Survival outcomes
LB: Manuscript writing, data analysis. MS, IF, SAB, RHT, MT, RT, FJQ: data collection or management. JCC: data collection or management, project development. RJK: protocol/project development, data collection or management.
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no potential conflicts of interest.
This study was approved by the Ethical committee of Mayo Clinic (IRB 18-001622).
Informed consent was obtained from all patients’ parents included in the study.
- 15.von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077CrossRefGoogle Scholar
- 18.Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle- invasive bladder cancer with different sensitivities to front line chemo- therapy. Cancer 25:152–165Google Scholar